Montefiore Einstein Cancer Center Secures Prestigious Three-Year CoC Accreditation, Highlighting Excellence in Research and Care
Key Insights
Montefiore Einstein Comprehensive Cancer Center (search) (MECCC) has earned Three-Year Accreditation from the Commission on Cancer (search), maintaining its position among top U.S. cancer centers.
The center demonstrates exceptional commitment to research with over 320 active clinical trials and 80% participation from historically underrepresented groups, compared to 8% nationwide.
MECCC's innovative programs, including AI-driven lung cancer (search) screening, have contributed to a 12% reduction in stage 4 lung cancers in the Bronx, while maintaining high standards in surgical care and nursing education.
Montefiore Einstein Comprehensive Cancer Center (search) (MECCC) has reaffirmed its position as a leading cancer treatment facility by securing a Three-Year Accreditation from the Commission on Cancer (search) (CoC) of the American College of Surgeons (search) (ACS). This prestigious recognition follows MECCC's achievement of comprehensive status from the National Cancer Institute in 2023.
The CoC evaluation designated MECCC as "exceptional," particularly highlighting its outstanding performance in research initiatives, surgical excellence, and nursing education programs. This accreditation requires meeting or exceeding 38 quality care standards, with evaluations conducted every three years.
Research and Clinical Trial Leadership
MECCC's research program stands out nationally, with 235 members conducting high-impact, transdisciplinary research. The center manages over 320 active clinical trials, enrolling more than 1,000 patients. Notably, approximately 80% of trial participants come from historically underrepresented groups—a remarkable achievement compared to the national average of 8%.
Innovative Screening and Treatment Approaches
The center's commitment to advanced care is exemplified by its Lung Cancer (search) Screening Program and Follow-up ASessmenT of Lung Nodules Clinic (FAST-Clinic). This innovative initiative employs artificial intelligence to identify and monitor high-risk patients, resulting in a significant 12% reduction in advanced stage 4 lung cancers in the Bronx.
"By focusing on patient-friendly screening methods and sophisticated surgical diagnostic techniques, cancers are being discovered earlier, when they are most treatable with minimally invasive surgery," explained Dr. Brendon M. Stiles, Chief of Thoracic Surgery & Surgical Oncology at MECCC.
Excellence in Nursing Education and Patient Care
The center's nursing staff has demonstrated exceptional commitment to professional development, with nearly all 200 MECCC nurses participating in specialized oncology education courses. These programs range from essential oncology nursing to managing oncologic emergencies, complemented by research into social determinants of health and survivorship issues.
Maureen Scanlan, Senior Vice President and Chief Nurse Executive at Montefiore Einstein, emphasized the significance of their nurse-led educational initiatives: "Our educational initiatives are designed by nurses, for nurses – so having these efforts be recognized by the Commission on Cancer (search) is incredibly rewarding."
Comprehensive Care and Future Direction
Dr. Edward Chu, Director of MECCC, attributes this continued success to the center's exceptional team: "Our continued CoC accreditation reflects the tremendous talent and dedication of MECCC specialists in caring for patients of the Bronx and beyond." The center's comprehensive approach, combining scientific research, patient care, and community advocacy, continues to set new standards in cancer treatment and research.